MSCs affect the coagulation system and have been used to treat hemorrhages following HCT.59,112DSCs compared to BM-MSCs have more procoagulant tissue factor and a higher expression of CD55, complement regulatory activity.83Before and after infusion of MSCs and DSCs, the central venous line is flushed with low-dose heparin.92The safety studies have not revealed an increased risk of thrombosis following infusion of BM-MSCs or DSCs.86,87,91,113 In mice, 40 times higher doses of DSCs than are used clinically did not induce any thrombosis.90 Here, CD55 is linked to Venous thrombosis.